Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Belcher Pharmaceuticals, LLC
EIR
•Belcher Pharmaceuticals, LLC•May 13, 2016

Belcher Pharmaceuticals, LLC – FDA EIR, May 13, 2016

Record Details

Belcher Pharmaceuticals, LLC underwent a comprehensive FDA inspection from April 25 to May 13, 2016. This extensive audit covered cGMP, pre-approval, and post-approval requirements for human and animal drug manufacturing, specifically focusing on Quality, Production, and Laboratory Control Systems under the Food, Drug & Cosmetic Act. The inspection resulted in nine significant observations documented in an FDA Form 483. Prominent violations included deficiencies in laboratory records, such as incomplete instrument calibration and unestablished accuracy of test methods. Investigations into out-of-specification results lacked adequate conclusions and follow-up, and the quality control unit failed to fully implement its procedures. Other critical issues identified were unjustified deviations from written laboratory mechanisms, insufficient periodic visual examination of reserve drug samples for deterioration, and inadequate employee training in specific operational and good manufacturing practices. Furthermore, the firm did not consistently follow or contemporaneously document written production and process control procedures, and lacked formal written procedures for post-marketing adverse drug experience surveillance and reporting. Notably, three of these observations were repeats concerning the Quality System. Belcher Pharmaceuticals' President committed to submitting a written response outlining corrective actions within 15 business days. The FDA emphasized the firm's responsibility for regulatory adherence and informed them of potential enforcement actions, including warning letters, seizures, injunctions, and penalties, for continued non-compliance.

Company
Belcher Pharmaceuticals, LLC
Inspection date
May 13, 2016
Product type
drugs
Office
Florida District Office
People
  • Jessica L. Pressley (Pharmacy Compounding National Expert, Drug Specialist, Drug Specialist, Foreign Cadre)
  • Stephanie D. Crockett
  • Jennifer Lalama
  • Miguel A. Martinez
View Company Profile

ID · aa721f5e-d92c-4b81-89f3-a286367404a1

Violation Codes10
21.U.S.C. 355(a)21 CFR 211.100(b)21 CFR 21121 CFR 310.305(a)21 CFR 211.194(d)21 CFR 211.19221 CFR 211.25(a)21 CFR 211.165(e)21 CFR 211.160(a)21 CFR 211.170(b)

Full citation text and observation details available on the Dashboard.

Other documents for Belcher Pharmaceuticals, LLC
  • 483 - 2024-08-16August 16, 2024
  • 483 - 2022-11-04November 4, 2022
  • 483 - 2021-11-15November 15, 2021
  • EIR - 2019-05-24May 24, 2019
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Belcher Pharmaceuticals, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.